KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non-Current Assets: 2013-2025

Historic Other Non-Current Assets for Xenon Pharmaceuticals (XENE) over the last 5 years, with Sep 2025 value amounting to $7.1 million.

  • Xenon Pharmaceuticals' Other Non-Current Assets fell 4.78% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 4.78%. This contributed to the annual value of $7.5 million for FY2024, which is 1.35% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Other Non-Current Assets stood at $7.1 million, which was down 22.57% from $9.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Other Non-Current Assets high stood at $9.2 million for Q2 2025, and its period low was $7.1 million during Q3 2025.
  • Its 3-year average for Other Non-Current Assets is $7.7 million, with a median of $7.5 million in 2024.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Other Non-Current Assets dropped by 8.20% in 2024, and later increased by 23.89% in 2025.
  • Quarterly analysis of 4 years shows Xenon Pharmaceuticals' Other Non-Current Assets stood at $7.8 million in 2022, then dropped by 4.58% to $7.4 million in 2023, then climbed by 1.35% to $7.5 million in 2024, then declined by 4.78% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, $9.2 million for Q2 2025, and $8.1 million during Q1 2025.